Skip to main content

Applications for this competition are due on January 7, 2022 no later than 5 PM PST. 

This competition will provide awards of up to $40,000 each (total direct costs) along two tracks, with a specific emphasis on projects capable of significant impact within 1-2 years.

Applications are categorized into two tracks:

  • Track 1 projects are basic, translational, or population-based cancer science projects limited to one year. These applications are expected to generate pilot data necessary for obtaining peer-reviewed extramural grants (such as an NIH R01) or enable additional data collection to respond to prior critiques for resubmission applications (NIH A1 applications).
  • Track 2 projects support Early Phase Clinical Research, with the goal of launching an interventional investigator-initiated interventional clinical trial at UCI Health within a 2-year time frame. While Track 2 projects are not necessarily expected to lead to extramural peer-reviewed funding, pharmaceutical industry co-sponsorship is encouraged. These projects must be managed by the Stern Center for Cancer Clinical Trials & Research and must meet the following criteria:
    • Be developed in collaboration with a CFCCC Disease-Oriented Team or a multidisciplinary tumor board
    • Include a DOT-approved clinical protocol
    • Be capable of obtaining full regulatory approval (e.g., IRB) within 6 months of the award.

The CFCCC will prioritize funding for projects in the following areas:

  • Research addressing cancer health disparities in the CFCCC catchment area of Orange County. This includes:
    • Cancers with unusually high rates of incidence, prevalence or mortality in the catchment area, such as melanoma, breast and lung cancer
    • Cancers disproportionately affecting racial or ethnic groups in Orange County, such as liver and gastric cancer in Hispanics and Asians, cervical, gall bladder, and young onset colorectal cancer in Hispanics
    • Projects that address unique aspects of a specific cancer burden in the catchment area (e.g., etiology of lung adenocarcinoma in Asian female never-smokers or of Ph-like B-lymphoblastic leukemia in Hispanics; basis for low HPV vaccination rates in different racial/ethnic groups; melanoma detection/prognosis in Hispanics)
  • Projects that include community engagement in the research development, methods, analyses, and/or dissemination of results
  • Collaborations between members of the Cancer Control Program with one or both of the other CFCCC research programs (Biotechnology, Imaging & Drug Development, and Systems, Pathways & Targets)
  • Research supporting the development of an Investigator-Initiated Trial in the detection or prevention of cancer, with the ultimate goal of obtaining extramural funding
  • Collaborations involving Disease-Oriented Teams or multidisciplinary tumor boards that seek to advance a novel diagnostic or screening technology, therapeutic molecule or device, or bio-behavioral intervention to a clinical trial
  • Basic, translational or investigator-initiated clinical research on cancers impacting the pediatric and adolescent/young adult population

Details on catchment area demographics and cancer incidence and mortality can be found at:

ACC Letter of Intent Form
ACC Application Form